A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer

Joseph C. Allegra, Thomas M. Woodcock, Stephen P Richman, Kirby I. Bland, James L. Wittliff

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.

Original languageEnglish
Pages (from-to)93-99
Number of pages7
JournalBreast Cancer Research and Treatment
Volume2
Issue number1
DOIs
StatePublished - Mar 1 1982
Externally publishedYes

Fingerprint

Conjugated (USP) Estrogens
Tamoxifen
Methotrexate
Fluorouracil
Breast Neoplasms
Platelet Count
Leukocyte Count
Estrogen Receptors
Drug Therapy
Therapeutics

Keywords

  • breast cancer
  • chemotherapy
  • combination chemo-hormonal therapy
  • endocrine therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. / Allegra, Joseph C.; Woodcock, Thomas M.; Richman, Stephen P; Bland, Kirby I.; Wittliff, James L.

In: Breast Cancer Research and Treatment, Vol. 2, No. 1, 01.03.1982, p. 93-99.

Research output: Contribution to journalArticle

Allegra, Joseph C. ; Woodcock, Thomas M. ; Richman, Stephen P ; Bland, Kirby I. ; Wittliff, James L. / A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. In: Breast Cancer Research and Treatment. 1982 ; Vol. 2, No. 1. pp. 93-99.
@article{65d5de4204bf4e0a9471959d2dc7629c,
title = "A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer",
abstract = "Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72{\%}, and 14 of 25 (56{\%}) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50{\%} complete remission rate and minimal toxicity.",
keywords = "breast cancer, chemotherapy, combination chemo-hormonal therapy, endocrine therapy",
author = "Allegra, {Joseph C.} and Woodcock, {Thomas M.} and Richman, {Stephen P} and Bland, {Kirby I.} and Wittliff, {James L.}",
year = "1982",
month = "3",
day = "1",
doi = "10.1007/BF01805721",
language = "English",
volume = "2",
pages = "93--99",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer

AU - Allegra, Joseph C.

AU - Woodcock, Thomas M.

AU - Richman, Stephen P

AU - Bland, Kirby I.

AU - Wittliff, James L.

PY - 1982/3/1

Y1 - 1982/3/1

N2 - Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.

AB - Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.

KW - breast cancer

KW - chemotherapy

KW - combination chemo-hormonal therapy

KW - endocrine therapy

UR - http://www.scopus.com/inward/record.url?scp=0020316040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020316040&partnerID=8YFLogxK

U2 - 10.1007/BF01805721

DO - 10.1007/BF01805721

M3 - Article

VL - 2

SP - 93

EP - 99

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -